TY  - JOUR
AU  - Gavilá, Joaquín
AU  - Oliveira, Mafalda
AU  - Pascual, Tomás
AU  - Perez-Garcia, Jose
AU  - Gonzàlez, Xavier
AU  - Canes, Jordi
AU  - Paré, Laia
AU  - Calvo, Isabel
AU  - Ciruelos, Eva
AU  - Muñoz, Montserrat
AU  - Virizuela, Juan A
AU  - Ruiz, Isabel
AU  - Andrés, Raquel
AU  - Perelló, Antonia
AU  - Martínez, Jerónimo
AU  - Morales, Serafín
AU  - Marín-Aguilera, Mercedes
AU  - Martínez, Débora
AU  - Quero, Juan C
AU  - Llombart-Cussac, Antonio
AU  - Prat, Aleix
PY  - 2019
DO  - 10.1186/s12916-018-1233-1
UR  - http://hdl.handle.net/10668/13391
T2  - BMC medicine
LA  - en
KW  - Breast cancer
KW  - HER2
KW  - HER2-enriched
KW  - PAM50
KW  - cardiac safety
KW  - intrinsic subtypes
KW  - neoadjuvant
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Cardiotoxicity
KW  - Chemotherapy, Adjuvant
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Paclitaxel
KW  - Polyethylene Glycols
KW  - Receptor, ErbB-2
KW  - Trastuzumab
TI  - Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
TY  - research article
VL  - 17
ER  -